Afficher la notice abrégée

Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network

dc.rights.licenseopenen_US
dc.contributor.authorGANDOLFO, Pauline
dc.contributor.authorSOEIRO, Thomas
dc.contributor.authorJOUVE, Elisabeth
dc.contributor.authorREVOL, Bruno
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDAVELUY, Amelie
dc.contributor.authorBERTIN, Celian
dc.contributor.authorEIDEN, Celine
dc.contributor.authorGIBAJA, Valerie
dc.contributor.authorCHAOUACHI, Leila
dc.contributor.authorPERAULT-POCHAT, Marie-Christine
dc.contributor.authorCHEVALLIER, Cecile
dc.contributor.authorAQUIZERATE, Aurelie
dc.contributor.authorLE BOISSELIER, Reynald
dc.contributor.authorCARTON, Louise
dc.contributor.authorLAPEYRE-MESTRE, Maryse
dc.contributor.authorFRAUGER, Elisabeth
dc.contributor.authorLACROIX, Clemence
dc.contributor.authorMICALLEF, Joelle
dc.date.accessioned2024-03-13T08:46:57Z
dc.date.available2024-03-13T08:46:57Z
dc.date.issued2024-02-19
dc.identifier.issn1472-8206 (Electronic) 0767-3981 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/188752
dc.description.abstractEnBACKGROUND: Due to its psychoactive effects, ketamine has become a drug used for non-medical purpose. OBJECTIVES: To assess the latest trends in ketamine use among people with substance use disorder and to characterize its clinical complications using complementary health data sources of the French Addictovigilance Network. METHODS: First, we extracted all reports involving ketamine from 2012 to 2021 from the database of the OPPIDUM program (i.e., a multicentric program conducted in collaboration with hundreds of substance abuse treatment facilities that collects data on drugs used by subjects with substance use disorders). We described the reports globally and the changes from 2012 to 2021. Second, we extracted all cases involving ketamine from July 2020 to December 2022 from the French National Pharmacovigilance Database (BNPV). We identified the cases related to ketamine use among people with substance use disorder and described them. RESULTS: There was a 2.5-fold increase in the number of ketamine users with substance use disorder in the OPPIDUM program, from 35 (0.7%) subjects in 2012 to 89 (1.7%) subjects in 2021. There was an increase in the proportion of subjects who were daily users, had distress upon discontinuation, and presented addiction. There were 238 cases related to ketamine use among people with substance use disorder in the French National Pharmacovigilance Database from July 2020 to December 2022. Among them, 94 (39.5%) cases involved ketamine use disorder, 20 (8.4%) cases involved urinary tract and kidney symptoms, and 13 (5.5%) cases involved hepatobiliary symptoms. CONCLUSION: The trend observed over 10 years reflects the growth in ketamine use among people with substance use disorder, although it does not allow to estimate the rates of non-medical use of ketamine in the general population. Ketamine-induced uropathy and cholangiopathy are reported in ketamine users with substance use disorder, especially in case of repeated and/or prolonged use of high doses.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAddictovigilance
dc.subject.enDrug abuse
dc.subject.enKetamine
dc.subject.enSubstance use disorder
dc.title.enPatterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network
dc.title.alternativeFundam Clin Pharmacolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/fcp.12995en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38372190en_US
bordeaux.journalFundamental & Clinical Pharmacologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04502174
hal.version1
hal.date.transferred2024-03-13T08:46:59Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Fundamental%20&%20Clinical%20Pharmacology&rft.date=2024-02-19&rft.eissn=1472-8206%20(Electronic)%200767-3981%20(Linking)&rft.issn=1472-8206%20(Electronic)%200767-3981%20(Linking)&rft.au=GANDOLFO,%20Pauline&SOEIRO,%20Thomas&JOUVE,%20Elisabeth&REVOL,%20Bruno&DAVELUY,%20Amelie&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_FundamClinPharmacol_2024_G ...
Taille:
1.344Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée